...focus: Cancer Clinical status: Phase I/II Founded: 2003 through the merger of Cureon A/S and Pantheco A/S...

...all therapeutic rights to LNA when it was formed through a merger of Cureon and Pantheco A/S...

...Sput out from Exiqon in December 1999. Cureon, now called Santaris after its merger with Pantheco...

...a range of biochemical and biological properties suitable for antisense compounds. Cureon subsequently merged with Pantheco A/S...
...the fact that Cureon had technology but was was planning a new financing round, while Pantheco...

...cash, which Santaris said should last two to three years. Santaris will be headquartered at Pantheco's...
...were in merger talks in March (see BioCentury, March 17). Cureon A/S , Copenhagen, Denmark Pantheco A/S...

...CEO from CEO of Cureon A/S ; and Lars Tonnesen to CFO from CEO of Pantheco A/S...

...Cureon said they are in merger talks. Cureon focuses on Locked Nucleic Acids (LNA), and Pantheco...
...four years. A final decision is expected in early April. Cureon A/S , Copenhagen, Denmark Pantheco A/S...

...Cancer companies Pantheco (Copenhagen, Denmark) and Cureon (Copenhagen, Denmark) said they are in merger talks. Cureon's...
...are in merger talks. Cureon's technology is based on a Locked Nucleic Acids (LNA), and Pantheco...

...HeLa cell cultures infected with the E. coli K12 strain without toxicity to mammalian cells. Pantheco A/S...

...drugs. Zydus will undertake chemistry, preliminary screening and initial characterization of compounds with antibacterial activity. Pantheco...
...development. Each company will cover its own R&D costs, and profits will be shared 50-50. Pantheco A/S...